Home Blog Page 1718

Helios 50 MW BESS achieves commercial operations in Hokkaido, Japan

TOKYO, Dec. 1, 2025 /PRNewswire/ — Manoa Energy (“Manoa” or the “Company”) today announced the start of commercial operations for the Helios 50MW Battery Energy Storage System (“BESS”) in Sapporo City, Hokkaido, Japan.

The Helios 50MW / 104 MWh BESS was developed in partnership with Brawn and HD Renewable Energy Japan (HDJP) by Brawn’s 100% owned Japan based development platform Manoa Energy (“Manoa”). 

“Successful completion of our first standalone Extra High Voltage BESS asset emphasizes our commitment to sustainable infrastructure investment in Japan. Brawn will continue to develop our additional 1GW pipeline of Extra High Voltage and High Voltage assets throughout Japan, for commercial operations between 2026 and 2030.” said Scott Reinhart, CEO of Brawn.

Helios construction began in April 2024. The project uses Tesla Megapack 2XL batteries, while Engineering, Procurement and Construction (EPC) was managed by HOKKAIDENKO Corporation. The Helios asset is a 100% merchant BESS which will participate in the wholesale, balancing, and capacity markets.

Dean Cooper, Head of Manoa Energy and COO of Brawn said “Japan’s energy storage sector is experiencing rapid acceleration, positioning Japan among the world’s most dynamic energy storage markets. Manoa Energy is excited to be part of Japan’s energy transition momentum, as the country emphasizes battery energy storage systems as a strategic priority for its critical energy infrastructure.”

About Brawn 

Brawn is an alternative investment manager focused on accelerating the energy transition across the Asia-Pacific region. With over 300+ projects purchased to date and a proven track record in renewable energy and infrastructure, Brawn specializes in originating, developing, and managing utility-scale projects, particularly in energy storage and clean energy solutions.

Along with its Japan energy storage portfolio, Brawn is also a strategic partner with Singapore based DDSP – a developer of next-generation digital and decarbonized energy infrastructure across Asia-Pacific. Focused on delivery for hyperscale clients alongside long-term operational partners, DDSP combines deep sectoral expertise across technical, operational, and investment disciplines to deliver and scale infrastructure in complex, underserved, and high-growth markets

Committed to global ESG principles, Brawn delivers sustainable investments that drive decarbonization while creating long-term value for stakeholders.

YEAHKA’s Q3 In-Store E-Commerce Business Sustains Profitability, Partnering with Renowned Brands Such as Midea, Toshiba, and China Telecom

HONG KONG, Nov. 28, 2025 /PRNewswire/ — YEAHKA Limited (Stock Code: 9923.HK), a leading commerce enablement technology platform, issued a voluntary announcement. The report revealed that the Company’s value-added services business continued to demonstrate high-quality growth and robust profitability in the third quarter of 2025.

Its in-store e-commerce business performed particularly well, achieving monthly profitability consecutively since the second quarter. Under a more stable business model, YEAHKA successfully expanded in both domestic and overseas markets, with its business brand QIANQIANHUI having served renowned chains including Midea, Toshiba, China Telecom, COLMO, and Li Shan Shan Tea House.

It is particularly noteworthy that the Company became one of the first Douyin service providers in the Hong Kong SAR and Macau regions during the third quarter. Currently, YEAHKA offers online marketing services to overseas merchants in locations including Hong Kong (China), Macau (China), and Singapore. Through localized marketing strategies and innovative approaches, it has successfully helped local F&B brands attract customer traffic both domestically and internationally.

The owner of Ha Ming Kee, a Hong Kong chain restaurant, stated in an interview that with YEAHKA’s in-store e-commerce services, inviting influencers for authentic content creation, the proportion of mainland Chinese tourists at its Tak Shing branch reached 30% within just over a year. Prior to the promotion, the store had almost no mainland customers. But now, many tourists specifically visit to dine after sightseeing nearby.

Regarding domestic operations, YEAHKA has partnered with the leading home appliance brand Midea, providing local lifestyle services. Using diverse methods such as livestreaming and short videos, it has generated greater exposure for Midea’s brand and products, driving sales and achieving brand building at the same time.

To date, YEAHKA and Midea have jointly executed several major livestreaming events. Specifically, the in-store e-commerce team recently collaborated with Midea on an outdoor livestream from Jiuzhaigou, taking users on a online tour of the scenic area. By setting the livestream within a national-level IP landscape, they built a high-value brand perception, attracting a large audience of viewers and generating orders.

Singapore businesses lead in AI and data adoption, but face cybersecurity challenges

  • Strong adoption of AI tools among Singapore businesses
  • Current cybersecurity readiness can be enhanced
  • High AI adoption boosts productivity, but human oversight is essential

SINGAPORE, Dec. 1, 2025 /PRNewswire/ — Singapore businesses are rapidly embracing digital transformation, with strong uptake of artificial intelligence (AI) and data analytics tools, but continue to lag in cybersecurity maturity, according to the latest survey by global professional accounting body CPA Australia.

Technology adoption for businesses in Singapore in 2025.
Technology adoption for businesses in Singapore in 2025.

The annual Business Technology Survey found that 95 per cent of businesses in Singapore use data analytics and visualisation software such as Python, Power BI and Excel, slightly above the survey average of 93 per cent.

Artificial Intelligence (AI) adoption follows closely at 92 per cent, also ahead of the survey average of 89 per cent. Nearly one in five organisations in Singapore have deeply embedded AI across their business operations, positioning Singapore as a front-runner in strategic AI use.

However, the most common form of AI use remains ad-hoc and occasional adoption, reported by 44 per cent of organisations. This typically involves deploying readily available AI tools such as ChatGPT, Microsoft Copilot and Google Gemini, and using AI assistants embedded in productivity platforms such as Microsoft 365 and Google Workspace. 

CPA Australia Singapore Divisional President, and Digital Business and Risk Services Leader at PwC Singapore, Greg Unsworth, said: “Singapore’s strong foothold in AI reflects the nation’s continued push towards digital transformation and operational excellence. However, businesses must move beyond experimentation and strategically integrate AI across functions to unlock its full value.”

Despite the strong digital adoption, Singapore’s cybersecurity maturity remains a key vulnerability. Only 23 per cent of businesses have fully integrated cybersecurity into their business strategy and operations, below the survey average of 28 per cent.

Further, 69 per cent of businesses report using cybersecurity software, trailing the survey average of 81 per cent. This presents a deep concern as organisations may be exposed to increased risk as they expand their digital footprints.

The survey revealed that 17 per cent of organisations take a reactive approach to cyber threats, only responding to threats as they arise rather than through structured prevention. Additionally, 11 per cent are unsure how cybersecurity is managed internally, pointing to gaps in governance and communication.

“Cybersecurity must be a strategic priority as digital adoption accelerates,” Mr Unsworth said. “The rise of AI-enabled threats, from sophisticated phishing to deepfake impersonation, makes it critical for businesses to strengthen their cyber resilience. Trust must be earned and reinforced through every digital interaction.”

Respondents highlighted the notable benefits from AI adoption. Over the past year, Singapore businesses have leveraged technology to streamline workflows, automate repetitive tasks, and enabled greater speed and precision in decision-making. These gains have translated into better employee experiences, with staff spending less time on mundane tasks and more time on higher-value tasks. At the same time, customer experience has improved as organisations use AI to deliver more personalised, responsive and data-informed services.

However, these benefits are accompanied by challenges. Growing reliance on AI raises concerns around human oversight and accountability, especially in decisions requiring judgement or ethical considerations. Some organisations are experiencing job displacement in routine or entry-level roles, and many continue to struggle with integrating AI into legacy systems.

Cultural and organisational barriers, such as resistance to change and limited staff buy-in and lack of understanding and trust in AI technologies, also hinder adoption. These issues are compounded by high implementation costs, uncertain returns on investment, limited digital literacy among senior leaders, a shortage of technology talent, and intensifying data privacy and security concerns.

Despite these hurdles, AI remains essential for businesses looking to stay competitive.

CPA Australia member and Director & Head of OCISO, APJ for Google Cloud, Daryl Pereira said: “AI’s potential is transformative, yet it remains a powerful co-worker, not a replacement for human ingenuity. As businesses accelerate AI adoption, they must be deliberate in preserving and elevating valuable human skills. The shift requires organisational leadership to proactively rethink roles, redesign workflows, and invest heavily in continuous learning. By prioritising upskilling and fostering cross-functional collaboration, companies can maintain a competitive edge and empower their teams to innovate responsibly.”

As Singapore continues to lead in digital adoption, investing in cybersecurity maturity and fostering a culture of responsible innovation, businesses can unlock the full potential of AI and data to drive sustainable growth and global competitiveness.

About the survey

CPA Australia’s 5th annual Business Technology Survey was conducted between July and September 2025. It explores business technology trends across various sectors, business sizes and markets. The survey received responses from 1,117 accounting and finance professionals working in different markets, including Australia, Mainland China, Hong Kong SAR, Malaysia and Singapore. 44 per cent of respondents worked in companies with 500 or more employees, 29 per cent in companies with 50 to 499 employees and 28 per cent in companies with fewer than 50 employees.

About CPA Australia

CPA Australia is one of the largest professional accounting bodies in the world, with more than 175,000 members in over 100 countries and regions, including more than 8,600 members in Singapore. CPA Australia has been operating in Singapore since 1954 and opened our Singapore office in 1989. Our core services include education, training, technical support and advocacy. CPA Australia provides thought leadership on issues affecting the accounting profession and public interest Find out more at cpaaustralia.com.au

The Science of Longevity: Inside Prof. Mike Chan’s Vision for Living Stronger, Smarter, and Longer

BANGKOK, Dec. 1, 2025 /PRNewswire/ — Malaysia had a rare moment of reflection this year when former Prime Minister Tun Dr. Mahathir Mohamad turned 100. His milestone sparked public conversations about aging, vitality, and what it truly means to remain strong at any age.

Longevity Forum 120: Experts at Bangkok Summit Say Healthy and Long Lifespans Are Within Reach: A united front of global experts advancing regenerative medicine, AI-driven healthcare, cellular therapeutics, and translational research. This powerful gathering reflects the Summit’s commitment to cross-border medical collaboration.
Longevity Forum 120: Experts at Bangkok Summit Say Healthy and Long Lifespans Are Within Reach: A united front of global experts advancing regenerative medicine, AI-driven healthcare, cellular therapeutics, and translational research. This powerful gathering reflects the Summit’s commitment to cross-border medical collaboration.

For many, longevity still feels like a mystery. For Prof. Dato’ Sri Dr. Mike Chan, it is a science — one he has spent more than 40 years studying, researching teaching, and refining across Americas, Europe and Asia.

At the We Are The World Global Summit in Bangkok, Prof. Chan who represents the European Wellness Biomedical Group (EWBG), delivered one of the most talked-about sessions. His message was simple, but powerful:
 “Longevity means nothing without healthspan.”

It’s a line he repeats often, because it strikes at the heart of his life’s work. To him, living long is meaningless if we spend those extra years weak, bedridden, or dependent. The real goal, he argues, is to live long and stay functional — strong body, sharp brain, and an independent life.

Aging Begins Earlier Than We Realize

During his Bangkok keynote, Prof. Chan broke aging down in a way anyone could understand. Aging, he said, isn’t just about birthdays. It’s about how fast our organs wear out.

“Most organs don’t last 75 years, let alone 100,” he explained.

  • The heart starts aging around 40
  • The pancreas weakens from 55
  • The lungs show decline as early as 20
  • The brain accelerates aging after 65

That’s why two people of the same age can feel completely different — one energetic, one constantly fatigued.

Prof. Chan’s own biological test results became a talking point: even though he is in his 60s, his biological age measured just 46.

The Secret: Treat the Organ, Not the Age

One of Prof. Chan’s biggest breakthroughs is what he calls organ-based cellular therapy. In simple terms, different organs need different “building blocks” to repair themselves.

“You don’t use the same part to fix the heart, the liver, the brain, the pancreas,” he said.
 “A1 treats A1. B6 treats B6. Precision matters.

This method has attracted global attention — especially among patients with:

  • Memory decline
  • Metabolic disorders
  • Hormonal imbalance
  • Neurological issues
  • Early signs of aging

The principle is straightforward: instead of only treating symptoms, repair the organ at its root.

The DDRR System — A Roadmap to Living Younger, Longer

At the core of Prof. Chan’s practice is a four-step system known as DDRR:

1. Diagnose

Using advanced tools like OG Scans, bone density imaging, ultrasounds and blood analysis, the goal is to detect problems before they appear.

2. Detox

Flushes out inflammation, toxins, and heavy metals — the silent accelerators of aging.

3. Repair

Rebuilds what has been damaged through hyperbaric oxygen therapy, mitochondrial repair, hormonal balancing and tissue-strengthening treatments.

4. Rejuvenate

The “age-reversal” stage where organ-specific precursor cells, peptides and mitochondria boosters help restore vitality.

This system is already being used in more than 40 wellness centers worldwide, from Germany and Switzerland to Malaysia and Thailand.

Why Longevity Matters Now

People today fear growing old with sickness more than growing old itself. Prof. Chan says the goal of longevity is not to simply extend years, but to extend quality.

He often shares cases of elderly patients regaining mobility, parents seeing improvements in neurodiverse children, and seniors feeling mentally sharper after years of decline.

Long life is meaningless without strength, clarity and independence,” he said in Bangkok.

Looking Ahead to 2026

Asia is fast becoming a global hub for longevity science, and demand for bioregenerative treatment is rising. New technologies — from AI-driven biological age tracking to advanced brain-rejuvenation protocols — are expected to define the next phase of medical progress.

For Prof. Chan, the mission remains unchanged:
 “Help people live younger, longer — with dignity and purpose.”

If 2025 was the year healthspan entered the mainstream, 2026 is shaping up to be the year longevity becomes a movement.

The Bioregenerative Sports Revolution: How Prof. Mike Chan Is Changing Athlete Recovery — From Sabah to the Super Bowl

KOTA KINABALU, Malaysia, Dec. 1, 2025 /PRNewswire/ — Big changes often start in small ways. For Sabah FC, a top Malaysian football club, it began with a simple agreement — a partnership with European Wellness, a medical group best known for anti-aging and precursor stem cell therapy.

Officials from European Wellness and Sabah FC: (Pictured, from left) Dr. Natassia Sarah, Prof. Mike Chan, Tuan Md Joh Haji Wid, and Tuan Shamsuddin Bin Mohd Shah — exchange club jerseys in a symbolic gesture marking their newly formalized partnership for athlete rehabilitation and sports-science collaboration.
Officials from European Wellness and Sabah FC: (Pictured, from left) Dr. Natassia Sarah, Prof. Mike Chan, Tuan Md Joh Haji Wid, and Tuan Shamsuddin Bin Mohd Shah — exchange club jerseys in a symbolic gesture marking their newly formalized partnership for athlete rehabilitation and sports-science collaboration.

But that one move is now shaking up the world of sports medicine.

Because what started in Sabah is now heading to the biggest sporting stage in the world: the Super Bowl.

And behind it all is a man who’s been preparing for this moment for over 40 years — Prof. Dato’ Sri Dr. Mike Chan.

How It All Started in Sabah

In late 2025, Sabah FC signed a deal with European Wellness Premier Center (EWPC) in Kota Kinabalu, Sabah. Their goal? To help players recover faster, avoid injuries, and stay at their best throughout the season — not just with physical therapy, but by treating their whole body from the inside out.

The club became the first in Malaysia to bring in bioregenerative medicine — a medical approach that focuses on healing, restoring, and rebuilding the body at the cellular level.

Sabah FC’s General Manager, Md Joh Wid, put it simply:
 “We want our players to come in good condition and leave in good condition.”

Prof. Mike Chan added:
 “Real endurance isn’t just about stamina. It’s about staying strong — even in extra time.”

What the Players Actually Get

This isn’t just about vitamins or spa treatments. Sabah FC players now undergo a special 4-step program: Diagnose, Detox, Repair, Rejuvenate.

Here’s what that means in plain terms:

  • Players get a full health check to spot issues early
  • They flush out harmful toxins that slow down recovery
  • They receive treatments to help damaged muscles and organs heal faster
  • Finally, they boost their energy, focus, and strength from within — often using safe, natural therapies like oxygen treatments and nutritional support

Why It Works

Regular training and rehab treat what you can see: sore muscles, swelling, maybe a twisted ankle. But what about the stuff you can’t see — like tired organs, stress hormones, or long-term wear and tear?

That’s where Prof. Chan’s method comes in. It’s used by celebrities, high-level executives, and now — footballers.

His treatments help with:

  • Fatigue
  • Recovery time
  • Mental sharpness
  • Joint strength
  • Even hormonal balance

And the best part? It’s tailored to each athlete’s body — no one-size-fits-all.

The Super Bowl Invitation

Just as the Sabah FC partnership was gaining attention, Prof. Chan got a call from the U.S. — from Leigh Steinberg, the famous NFL agent who inspired the movie, Jerry Maguire.

Steinberg invited Prof. Chan to speak during Super Bowl Week 2026, in front of NFL teams, doctors, and athletes. Why? Because the NFL is looking for real solutions to a major problem: concussions and brain injuries.

Prof. Chan has spent years working on brain-specific treatments — using safe, organ-targeted cell therapy to help people with memory loss, autism, and yes, sports-related brain damage.

As he explains:
 “You can’t treat all injuries with the same solution. A knee needs knee treatment. A brain needs brain therapy. Precision matters.”

What It Means for Sports in 2026

This is just the beginning.

Thanks to Sabah FC, Southeast Asia is now leading the way in next-gen athlete care. And with the Super Bowl platform, the rest of the world is starting to pay attention.

Other sports may soon follow — including rugby, MMA, and Olympic teams — all exploring new ways to keep their athletes strong, focused, and injury-free for longer.

Prof. Chan’s premier center in Kota Kinabalu is now being called ASEAN’s hub for elite athlete regeneration.

Looking Ahead

2025 was the start.
2026 could be the global breakthrough.

The science is ready. The results are promising. And the sports world is finally open to new ideas.

Athletes deserve better than rest and painkillers. They deserve real recovery.
And thanks to Prof. Mike Chan — that’s exactly what they’re starting to get.

Perlis Royalty Join Prof. Mike Chan in Strengthening Malaysia’s Fight Against Autism

KUALA LUMPUR, Malaysia, Nov. 30, 2025 /PRNewswire/ — Malaysia’s drive to modernize autism care received strong support today when the Raja Muda of Perlis, Tuanku Syed Faizuddin Putra Jamalullail, and his consort, Tuanku Dr. Hajah Lailatul Shahreen Akashah Khalil, attended the International Congress on Advances in Autism, Neurodevelopmental & Neurodegenerative Disorders (ICAANND 2025) in Kuala Lumpur. Their appearance signalled rising national commitment to early diagnosis, intervention capacity and improved support for neurodiverse families. ICAANND 2025 was organized by the European Wellness Biomedical Group (EWBG). 

Prof. Dato’ Sri Dr. Mike Chan and the ICAANND 2025 international faculty stand alongside the Raja Muda of Perlis, Tuanku Syed Faizuddin Putra Ibni Tuanku Syed Sirajuddin Jamalullail and Raja Puan Muda,  Tuanku Dr. Hajah Lailatul Shahreen Akashah binti Khalil during a special appreciation segment honouring speakers at Glamhall, Damansara.
Prof. Dato’ Sri Dr. Mike Chan and the ICAANND 2025 international faculty stand alongside the Raja Muda of Perlis, Tuanku Syed Faizuddin Putra Ibni Tuanku Syed Sirajuddin Jamalullail and Raja Puan Muda, Tuanku Dr. Hajah Lailatul Shahreen Akashah binti Khalil during a special appreciation segment honouring speakers at Glamhall, Damansara.

The royal presence aligned with the scientific direction championed by Prof. Dato’ Sri Dr. Mike Chan, whose two decades of global research have positioned him as one of Asia’s leading voices in precision neuro-generation.

Rising Needs in Malaysia

Perlis, like many parts of the country, has seen an increase in autism prevalence among school-aged children. Through UniMAP and the A-HEART Autism Hub, the Perlis royal household has invested in early identification, teacher training and family support programs. Their visit in Kuala Lumpur highlighted the need to extend such efforts nationally.

Prof. Mike Chan’s Global Autism Mission

Prof. Chan’s work on autism began more than a decade ago in Baoding, China, where he trained paediatric teams to improve diagnostic accuracy and early detection. These early initiatives helped shape his long-term approach to neurodevelopmental conditions.

His wellness centers have consistently documented two major biological patterns among autistic children: severe gut dysfunction and heavy-metal accumulation. “Your gut has more brain cells than your brain. If you do not fix the gut, you cannot fix the child,” Prof. Chan told delegates at the Bangkok Summit.

His model of care is built on precision. It combines intestinal mucosa precursors with brain-region-specific support to target key areas such as the frontal lobe, hippocampus and cortex. This organ-specific strategy parallels the scientific work published in his Human Cytology Atlas, which maps more than 400 human cell types.

A Turning Point in the United States

In April 2025, Prof. Chan presented at the Autism Summit in San Diego, where United States presidential candidate Robert F. Kennedy Jr. pledged to “find an answer for autism by September.” The event drew global attention and intensified discussions on early intervention and scientific pathways.

At the summit, Prof. Chan emphasized that autism cannot be treated with generic or broad-spectrum approaches. He stressed that each organ and brain region require specific precursor support and that the future of autism care lies in precision, early detection and environmental correction.

Royal Recognition in Kuala Lumpur

In Kuala Lumpur, Prof. Chan presented an Appreciation Plaque to the Raja Muda of Perlis in recognition of the royal household’s dedication to autism advocacy. Although their visit was brief, it carried national significance and underscored growing unity between scientific leadership and state-level action.

“We saw the passion of the Perlis royal household first hand,” Prof. Chan said. “They care deeply about children, families and the future of autism services in Malaysia.”

Malaysia’s Path Forward

With scientific frameworks refined in Baoding, amplified in San Diego and Bangkok, and supported by Malaysian royalty, Prof. Chan says Malaysia is entering a critical new phase. The country is increasingly positioned to lead regional efforts in advanced autism intervention and neurodevelopmental research.

“No child should be left behind,” he said. “Every family deserves access to proper autism support, no matter where they live.”

As Malaysia aligns scientific capability, leadership and public awareness, its role in the global autism movement continues to grow.

Media Contact: 

Justin Chew & Gerald Chuah
Media Team
media@european-wellness.com 

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

–  Utilizing Ascletis’ Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9, 30, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to-head non-human primate (NHP) studies.

–  ASC37 oral tablets’ drug exposure, as measured by the area under curve (AUC), was approximately 57-fold of retatrutide’s drug exposure in head-to-head NHP studies.

–  Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.

–  ASC37 in vitro activity was approximately 5-, 4- and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.

–  Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 oral tablets is expected in the second quarter of 2026.

–  The Company will host a conference call in Mandarin at 10:00 a.m. China Standard Time on December 1, 2025.

HONG KONG, Nov. 30, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that it has selected ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 oral tablets for the treatment of obesity in the second quarter of 2026.

ASC37 oral tablets is the Company’s first incretin drug candidate developed with its proprietary Peptide Oral Transport ENhancement Technology (POTENT). 

ASC37, a GLP-1R, GIPR, and GCGR triple peptide agonist, was discovered and optimized in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). ASC37 in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.

Utilizing Ascletis’ POTENT technology, ASC37 oral tablets achieved average absolute oral bioavailability[2] of 4.2%, which was approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC [3] formulation, respectively, in head-to-head non-human primate (NHP) studies. Furthermore, after oral administration, ASC37 oral tablets’ drug exposure, as measured by the area under curve (AUC), with the POTENT formulation was approximately 57-fold of retatrutide’s drug exposure with the oral SNAC formulation, in head-to-head NHP studies.

Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.

 “Selection of ASC37, a promising oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development once again demonstrates our strong R&D capabilities and our commitment to address the unmet needs for the treatment of obesity,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Leveraging our proprietary technology platforms, including AISBDD and POTENT, Ascletis has successfully established a highly competitive, differentiated and diverse pipeline portfolio which can potentially effectively address the various treatment needs of patients with obesity and other metabolic diseases.”

[1] GLP-1R: glucagon-like peptide 1 receptor, GIPR: gastric inhibitory polypeptide receptor, GCGR: glucagon receptor

[2] absolute oral bioavailability: the percentage of an orally administered drug that reaches the systemic circulation (bloodstream), compared to an intravenous (IV) dose of the same drug

[3] SNAC: Salcaprozate Sodium

Conference Call

Ascletis will host a conference call in Mandarin at 10:00 a.m. China Standard Time on December 1, 2025. A live webcast of the call will be available via Tencent Meeting/ VooV Meeting, with the Meeting ID: 495-266-842, or access links of:

Chinese Mainland: https://meeting.tencent.com/dm/10ve6whW8Rbl; or

International: https://voovmeeting.com/dm/10ve6whW8Rbl.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com 

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com 

Xinhua Silk Road: Discover China with foreign friends

BEIJING, Nov. 30, 2025 /PRNewswire/ — Do you want to visit China? How to travel as convenient as a local resident? You can learn from this guide! There are three foreign residents from different countries to show you the mobile payments, transportation and local cuisine. Come and get the shortcut!

 

Original link: https://en.imsilkroad.com/p/348542.html